Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this an...

Full description

Saved in:
Bibliographic Details
Published in:Clin Transl Sci
Main Authors: Ou, Ying C., Liu, Lucy, Tariq, Bilal, Wang, Kun, Jindal, Ashutosh, Tang, Zhiyu, Gao, Yuying, Sahasranaman, Srikumar
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2021
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993273/
https://ncbi.nlm.nih.gov/pubmed/33306268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12948
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items